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Abstract
Introduction. Atrial fibrillation (AF) is the most common supraventricular arrhythmia. It results in an increased frequen-
cy of thromboembolic complications and a higher death rate. The frequency of arrhythmia is steadily increasing, and 
a sustained growth in the number of patients with AF can be expected in the coming years. Thromboembolic episodes 
are the most serious complications of AF. Anticoagulant treatment, based on recommendations, is considered to be 
the priority action in patients with AF.
The aim of this paper is to evaluate compliance with guidelines for the prevention of thrombosis, recommended on 
discharge, in patients with non-valvular AF, who were hospitalised in a cardiology ward.
Methods and materials. 4,099 patients with non-valvular AF, who had been hospitalised and discharged from a cardio-
logy ward between 2004 and 2012, were subject to a retrospective analysis. We assessed the risk of thromboembolic 
(via CHADS2 score) and haemorrhagic (via HAS-BLED score) complications, as well as data on comorbid conditions and 
the recommended anticoagulant prevention. The compliance of the prevention of thromboembolic complications with 
the guidelines was assessed according to the applied anticoagulant and antiplatelet treatment in particular groups of 
thromboembolism risk.
Results. The average age of the examined group was 70.6 (± 10.9) years. AF co-existed most frequently with the follo-
wing diseases: hypertension (74.8%), ischaemic heart disease (56.7%), and heart failure (54.8%). A low risk of thrombo-
embolic complications was reported in 7.2% of patients, whereas 25.4% were rated as moderate risk, and 67.4% as high 
thromboembolic risk. A high risk of bleeding was reported in 34.6% of patients. In the prevention of thromboembolic 
complications, an oral anticoagulant, in monotherapy or in combination with antiplatelet drugs, was recommended for 
64% of patients on discharge. According to the guidelines, 66.9% of patients from the examined group qualified for the 
prevention of thromboembolic complications: 62.4% of those with a high risk of stroke, 86% of those with a moderate 
risk, and 41.1% of those without stroke risk factors. The highest percentage of patients treated pursuant to the gu-
idelines in the chosen clinical situations was to be seen among patients after a thromboembolic episode (70.8%). We 
found that in 73.8% of patients aged 65–74, and in 55.2% of patients over the age of 80, anticoagulant prevention was 
applied in accordance with the guidelines.
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Conclusions. On discharge from hospital, nearly two-thirds of patients with AF were subjected to the prevention of throm-
boembolic complications in accordance with the guidelines. Most often they belonged to the group of moderate risk, 
and least often to the group without thromboembolic risk factors. A high percentage of patients treated in line with the 
guidelines was seen in the patients who recovered from a thromboembolic episode. The percentage of patients with AF 
who were subjected to anticoagulant treatment in accordance with the guidelines decreased with age.
Key words: atrial fibrillation, CHADS2, scale, stroke
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not qualify for the prevention of thrombosis [7]. The latest 
recommendations underline that the primary goal is the 
identification of patients classified as having a “really low” 
thromboembolism risk, who do not qualify for anticoagulant 
treatment. All other patients, with the exception of those 
with contraindications, should undergo the therapy [6].
The aim of this paper is to evaluate compliance with 
the guidelines for applied prevention of thromboembolic 
complications in hospitalised patients with AF.
Material and methods
Medical data on 4,099 patients discharged from the 
Cardiology Clinic between 2004 and 2012 who had been 
diagnosed with AF was subject to retrospective analysis. If 
a patient had been hospitalised more than once, the data 
referring to their final hospital stay was analysed. The two 
criteria for exclusion from the study were valvular AF or the 
patient’s death during hospitalisation.
The study group consisted of patients hospitalised be-
tween 2004 and 2012. At this time, the CHADS2 score was 
the one primarily used. For this reason, the CHADS2 score 
was applied in this paper for the assessment of thrombo-
embolism risk. In the CHADS2 score, 0 points indicates a low 
risk of thromboembolism, 1 point indicates an intermediate 
risk, and 2 points or more indicates a high risk.
In assessing the risk of bleeding complications, the 
following factors were considered to increase the risk of 
bleeding according to the HAS-BLED score: anaemia, typi-
cally defined as haemoglobin levels of less than 13 g/dL 
in women and less than 12 g/dL in men, and thrombocy-
topenia (a concentration of blood platelets of less than 
150 G/L). A time in therapeutic range (TTR) value of less 
than 60% was considered the unstable International 
Normalised Ratio (INR). Valvular AF was defined as AF in 
patients with valve prosthesis or severe mitral stenosis.
The following factors were categorised as being com-
pliant with the applicable guidelines:
 — a lack of antithrombotic and antiplatelet therapy in 
patients with a low thromboembolism risk;
 — antiplatelet drug in monotherapy  in patients with a low 
and an intermediate thromboembolism risk;
Introduction
Atrial fibrillation (AF) causes a five-fold increased risk of 
stroke among patients with non-valvular AF [1]. The annual 
incidence of stroke among subjects with AF who were 
not treated with anticoagulants amounts to 4.9–5.7% 
[2, 3]. Thromboembolic complications are characterised 
by a poorer prognosis and a higher death rate among 
patients with arrhythmia than among those with sinus 
rhythm [4]. The use of prevention of thromboembolic 
complications among patients with AF is determined upon 
their thromboembolism risk, which depends on their age, 
sex and comorbid conditions. The CHA2DS2VASc score, 
which is the extension of the previously used CHADS2 
[Congestive heart failure, Hypertension, Age ≥ 75 (× 2), 
Diabetes, Stroke (× 2), vascular disease, age 65–74, sex 
category] score [5, 6], is currently applied to assess the 
thromboembolism risk. The risk of thromboembolic com-
plications is negligible in those patients with isolated AF 
(primarily patients under the age of 60), without comor-
bid conditions [7]. However, the number of patients with 
isolated AF constitutes only 2–15% of the overall number 
of patients suffering from this presentation of arrhythmia 
[8–11]. The identification of patients classified as having 
a high risk of thromboembolic complications, and thereby 
qualifying for anticoagulant treatment, has changed in 
recent years. According to the recommendations of the 
highest grade and the European guidelines from 2006 
and 2010 referring to the treatment of patients with AF, 
anticoagulant or antiplatelet therapy (depending on the 
stroke risk) was recommended for all patients with AF with 
the exception of those with isolated arrhythmia or in the 
presence of contradictions [5, 12].
The 2012 guidelines of the European Society of Car-
diology (ESC) represent a slightly different point of view 
with regard to the prevention of thromboembolic compli-
cations in patients with AF compared to the two previously 
mentioned documents. Based on the abundant evidence 
of the efficacy of oral anticoagulants (OAC) in preventing 
thromboembolic complications, as well as on the safety 
of applied therapy using new anticoagulants, the ESC re-
commended the identification of patients with AF who do 
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 — an oral anticoagulant in monotherapy in patients with 
an intermediate and a high thromboembolism risk 
and in patients with a low risk in the case of electrical 
cardioversion, provided that the episode of AF lasted 
at least 48 hours;
 — two antiplatelet drugs in combined therapy in patients 
with a low and an intermediate thromboembolism risk 
after acute coronary syndrome and/or percutaneous 
coronary intervention;
 — low-molecular weight heparin (LMWH) in patients with 
an intermediate and a high thromboembolism risk when 
bridging therapy was necessary.
The regional Bioethics Committee granted consent to 
conduct this study (no. 12/2011).
Statistical analysis
The data derived from the clinical study was subject to 
statistical analysis with the use of the Chi-square test to 
approximate the significance of distribution of random 
variables in single classifications and to evaluate the in-
terdependence of pair of factors in double classifications. 
The statistical evaluation of the significance of differences 
was designated with a p value (p < 0.05). The calculations 
were made using Med. Calc Ver. 12.4.0.0 software.
Results
Clinical characteristics of patients with AF
In the examined group of 4,099 participants, the number of 
women was 2,244 (54.7%). The average age of all patients 
was 70.6 (± 10.9) years, with an average age for men of 
68.2 (± 11.5) and for women of 73.5 (± 9.4) years. The 
most common type of arrhythmia was paroxysmal AF, which 
occurred in 1,904 patients (46.5%). Permanent AF was 
observed in 1,768 participants (43.1%), while persistent 
arrhythmia was diagnosed in 427 participants (10.4%). 
In the examined group, the following diseases co-existed 
most frequently with AF: hypertension in 3,067 subjects 
(74.8%), coronary artery disease in 2,324 subjects (56.7%), 
and heart failure in 2,247 subjects (54.8%) (as shown in 
Table 1). Patients suffering from AF were most commonly 
hospitalised for elective surgeries: implantation/reimplan-
tation of cardiac pacing system (1,422 patients — 34.7%), 
coronorography or coronary angioplasty (250 patients — 
6.1%), and electrophysiological test and/or ablation (57 
patients — 1.4%). Due to the exacerbation of a primary 
disease, 845 patients (20.6%) with AF were hospitalised. 
The majority of these patients were hospitalised due to 
heart failure decompensation which occurred in a different 
mechanism than AF with a high ventricular rate. Acute 
coronary syndrome caused hospitalisation among 587 
patients with AF (14.3%), while an AF attack led to the 
hospitalisation of 471 patients (11.5%).
In the examined group, for 297 participants (7.2%) there 
was no risk of thromboembolic complications (CHADS2 = 0). 
The CHADS2 score equalled 1 point in 1,042 (25.4%) and 
2 or more points in 2,760 participants (67.4%). According to 
the HAS-BLED score, a high risk of bleeding was observed in 
1,418 (34%), whereas a low risk was observed in 2,681 pa-
tients (65.4%). The risk of haemorrhagic complications 
was compared in groups with low, intermediate, and high 
thromboembolism risks. A high risk of bleeding (HAS-BLED 
≥ 3 points) was indicated in five patients (1.7%) without 
a thromboembolism risk, in 143 patients (13.7%) with an 
intermediate thromboembolism risk, and in 1,256 patients 
(45.5%) with a high stroke risk.
Antithrombotic prophylaxis  
in the study group
In the prevention of thromboembolic complications, OAC was 
recommended on discharge for 2,368 (57.8%) patients in 
monotherapy and for 259 (6.3%) patients in combination 
with antiplatelet drugs. In the study group, 863 (21.1%) 
patients received the antiplatelet drug [acetylsalicylic acid 
(ASA) or clopidogrel] in monotherapy, while 279 (6.8%) 
participants received two antiplatelet drugs in combination 
therapy. LMWH was recommended on discharge for 87 
patients (2.1%), whereas 243 patients (5.9%) received no 
antiplatelet and anticoagulant treatment. The prevention 
of thromboembolic events in patients with AF who were 
discharged from the hospital in particular groups with 
Table 1. Characteristics of a population with atrial fibrillation
Number  
of patients 
N = 4,099
Percentage 
of patients 
[%]
Concomitant diseases
Hypertension 3,067 74.8
Coronary artery disease 2,324 56.7
Heart failure 2,247 54.8
Impaired renal function 
(GFR < 60 mL/min)
2,206 53.8
Dyslipidaemia 1,897 46.3
Diabetes 893 21.8
Thyroid disease 667 16.2
Malignancy 173 4.2
Peripheral vascular disease 79 1.9
Previous thromboembolism
Stroke 434 10.6
Transient ischaemic attack 59 1.4
Other thromboembolism 80 2
GFR — glomerular filtration rate
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thromboembolism and bleeding risks is shown in Table 2. 
In a group of 1,904 patients with paroxysmal AF, OAC was 
recommended in monotherapy or in combination therapy 
for 1,036 patients (54.4%) on discharge, while antiplatelet 
drugs were applied for 733 patients (38.5%) on discharge. 
By means of comparison, OAC was prescribed to 1,289 
patients (72.9%) with permanent AF in the prevention of 
thromboembolic complications, whereas antiplatelet drugs 
were prescribed to 392 patients, which constituted 22.2% of 
those with permanent AF who were discharged from the hos-
pital. The highest percentage of participants discharged with 
recommendations for OAC was observed among patients 
with permanent AF — 358 (83.3%). For the purpose of sinus 
rhythm restoration by means of electrical conversion, 240 
patients with permanent AF were admitted to the hospital. 
This amounted to 52.6% of the examined subjects with this 
presentation of AF. 49 patients with permanent AF (11.5%) 
received on discharge antiplatelet drug(s), while 87 patients 
(4.9%) with paroxysmal AF, 20 (4.7%) with permanent AF 
and 87 (4.9%) with persistent arrhythmia were discharged 
without any prevention of thrombosis.
The evaluation of compliance  
with the guidelines for the prevention  
of thromboembolic complications
We concluded that, in accordance with the guidelines, 
the prevention of thromboembolic complications was 
applied for 2,740 out of 4,099 patients, which amounted 
to 66.9% of participants from the study group. Compliance 
of the prevention of thromboembolic complications recom-
mended on discharge was reported in:
 — 123 patients (41.1%) with a low (CHADS2 = 0) throm-
boembolism risk;
 — 896 patients (86%) with an intermediate (CHADS2 = 1) 
thromboembolism risk;
 — 1,721 patients (62.4%) with a high (CHADS2 ≥ 2) throm-
boembolism risk  (as shown in Table 3).
In the group of examined patients, the highest level 
of compliance of prescribing drugs with the applicable 
guidelines was observed among the subjects receiving 
OAC in monotherapy. OAC, recommended in monotherapy 
according to the guidelines, was prescribed to 93.4% of 
patients. However, this procedure was validated only in 
the 11.5% of patients who did not receive any prevention 
of thromboembolic complications. The application of anti-
platelet therapy in combination with ASA and clopidogrel 
(without OAC) was compliant with the applicable guidelines 
only in 19.9% of patients (Table 3).
Table 4 shows anticoagulant treatment in selected 
groups of patients. In the study group, the majority of pa-
tients treated with anticoagulants in line with the guidelines 
were aged 65–74 (940 participants — 73.8%).
Discussion
Our study has shown that two-thirds of hospitalised patients 
with AF received anticoagulant treatment in accordance 
with the guidelines based on the stratification of throm-
boembolism risk. The compliance of the applied therapy 
with the guidelines was at its highest level (86%) in the 
group of patients with an intermediate thromboembolism 
risk. Apparently, this results from the fact that it is possible 
Table 2. Anticoagulant prophylaxis recommended at discharge, and the risk of thromboembolic and haemorrhagic complications
Anticoagulant prophylaxis Thromboembolism risk Bleeding risk
Low CHADS2 
score = 0 
N = 297
Moderate 
CHADS2  
score = 1  
N = 1,042
High 
CHADS2  
score ≥ 2  
N = 2,760
P value Low  
HAS-BLED 
score = 0–2 
N = 2,681
High 
HAS-BLED 
score ≥ 3  
N = 1,418
P value
OAC in monotherapy or 
with antiplatelet drug(s) 
N = 2,626
180 (60.6%) 658 (63.2%) 1,788 
(64.8%)
< 0.0001 1,792 
(67.8%)
834 (58.9%) < 0.0001
Antiplatelet drug  
in monotherapy or  
two antiplatelet drugs  
in combined therapy 
N = 1,142
82 (27.6%) 297 (28.5%) 764 (27.7%) < 0.0001 683 (25.5%) 459 (32.4%) < 0.0001
Low-molecular weight 
heparin 
N = 87
7 (2.4%) 17 (1.6%) 63 (2.3%) < 0.0001 52 (1.9%) 35 (2.5%) 0.2469
Without anticoagulant 
and antiplatelet therapy 
N = 243
28 (9.4%) 70 (6.7%) 145 (5.2%) < 0.0001 154 (5.7%) 89 (6.3%) 0.4806
CHADS2 — Congestive heart failure, Hypertension, Age ≥ 75 (× 2), Diabetes, Stroke (× 2), vascular disease, age 65–74, sex category; N — number of patients; HAS-BLED — Hypertension, Abnormal renal/liver 
function, Stroke, Bleeding history or predisposition, Labile international normalised ratio, Elderly (> 65 years), Drugs/alcohol concomitantly; OAC — oral anticoagulants
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to apply OAC or ASA to a group of patients with AF whose 
CHADS2 score is 1 point. It was reported that 62% of sub-
jects with a high risk of thromboembolic complications 
received a proper anticoagulant therapy. The highest 
percentage of improper prevention of thrombosis was 
seen among patients with a low stroke risk. In a group of 
patients whose CHADS2 score was 2 or more points, the 
number who received proper treatment in this study was 
the same as that indicated in the GARFIELD Registry (62%) 
[13]. The average age of patients in the GARFIELD Registry 
(currently the biggest European registry of patients with 
AF) was 70 years, whereas the average age of patients 
who participated in our study was 71 years. Compared to 
the GARFIELD Registry, coronary artery disease occurred 
more often in patients who participated in the study (57% 
vs. 19%), as did heart failure (55% vs. 21%). By means of 
comparison, in the Euro Heart Survey on Atrial Fibrillation, 
58% of subjects were treated with anticoagulants pursuant 
to the guidelines [14].
Taking into consideration the fact that the patients 
participating in the study were older (the average age of 
patients in the European registry was 68) and suffered 
from more comorbid conditions than did subjects in the 
Euro Heart Survey (hypertension — 62%, coronary artery 
Table 3. Compliance with applicable guidelines regarding anticoagulant prophylaxis in patients of low, intermediate and high risks  
of thromboembolic events
Thromboembolism risk Without  
treatment 
N = 243
ASA or  
clopidogrel* in 
monotherapy 
N = 863
ASA 
+ clopidogrel 
N = 277
Antiplatelet 
drug(s) + OAC 
N = 258
OAC in mono-
therapy 
N = 2,368
LMWH 
N = 87
N [%]
Low (CHADS2 = 0) 
N = 297
28 65 2 + 15** 6 + 6** 159 + 9*** 7 123 (41.1)
Intermediate 
(CHADS2 = 1) 
N = 1,042
70 227 30 + 40** 34 + 20** 604 12 + 5**** 896 (86)
High (CHADS2 ≥ 2) 
N = 2,760
145 571 190 100 + 92** 1,599 33 + 30# 1721 
(62.4)
Patients treated  
according to  
the guidelines
28 (11.5) 292 (33.8) 55 (19.9) 118 (45.7) 2,212 (93.4) 35 (40.2)
*In the case of intolerance to acetylsalicylic acid (ASA); **after acute coronary syndrome; ***in the case of electrical cardioversion, provided that the episode of atrial fibrillation lasted at least 48 hours;  
#in the case of bridging therapy if necessary; N — number of patients; OAC — oral anticoagulant; LMWH — low-molecular weight heparin; CHADS2 — Congestive heart failure, Hypertension, Age ≥ 75 (× 2), 
Diabetes, Stroke (× 2), Vascular disease, Age 65–74, Sex category 
Text in red is consistent with treatment guidelines
Table 4. Compliance prevention of thromboembolism with the guidelines in the course of atrial fibrillation in selected groups of patients
Thromboembolism risk Patients treated according to the guidelines 
N [%]
Patients treated 
according  
to the guidelines 
N [%]
Selected groups of patients Low risk 
(CHADS2 = 0)
Intermediate risk 
(CHADS2 = 1)
High risk 
(CHADS2 ≥ 2)
Age 65–74 years 29 (44.6) 396 (85.9) 515 (40.4) 940 (73.8)
Stroke/TIA/other  
thromboembolism
0 0 394 (70.8) 394 (70.8)
Heart failure 0 180 (69.5) 1,276 (56.8) 1,535 (68.3)
Hypertension 0 505 (74.9) 1,566 (51) 2,071 (67.5)
Female gender 39 (43.3) 302 (77.4) 884 (47.6) 1,225 (66)
Diabetes 0 24 (92.3) 559 (62.6) 583 (65.3)
Vascular disease 14 (28.6) 201 (75.9) 506 (42.7) 721 (60.8)
Malignancy 4 (33.3) 26 (74.3) 74 (42.8) 104 (60.1)
Age ≥ 75 years 0 69 (84.1) 963 (56.6) 1,032 (59.1)
Age ≥ 80 years 0 28 (65.1) 456 (52) 484 (55.2)
N — number of patients; CHADS2 — Congestive heart failure, Hypertension, Age ≥ 75 (× 2), Diabetes, Stroke (× 2), Vascular disease, Age 65–74, Sex category; TIA — transient ischaemic attack
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disease — 32%), the number of patients with AF treated 
properly with anticoagulants in the Polish medical centre 
was high in relation to the European population. In the 
present study, OAC in monotherapy was received by 93% of 
patients in accordance with the guidelines. The percentage 
of patients treated properly by means of combined therapy 
(i.e. with OAC and one or two antiplatelet drugs) was lower 
(46%). In the Euro Heart Survey, OAC treatment was re-
ceived by 67% of patients to whom it was recommended, 
and by 49% of patients who did not qualify for prevention 
of thrombosis [14].
In the present study, 5.2% of patients with a high stroke 
risk received no therapy, whereas in the European registry 
patients with a high thromboembolism risk without antico-
agulant treatment constituted 7% of all subjects [14]. The 
percentage of patients classified as having a high stroke 
risk and treated with OAC was higher in German registries 
than in the present study. OAC was applied to 71% of 
patients in both the AFNET Registry [15] and the ATRIUM 
study [16]. However, the number of patients treated with 
OAC without a recommendation for such therapy was also 
high, and amounted in both studies to nearly 50%.
In the present study, the percentage of patients who re-
ceived OAC recommendations was 64%. Table 5 illustrates 
the application of OAC in studies published in recent years 
[13–24]. A sustained increase in the number of patients 
with AF treated with OAC, as well as excessive OAC recom-
mendations for patients with a low disease risk, can be 
observed. The high percentage of patients with a low risk 
of thromboembolic complications who receive OAC is no-
table in both the present study and the studies conducted 
by other authors.
According to the guidelines, the most significant factor 
upon which OAC is recommended is thromboembolism 
risk evaluated by means of CHADS2 and CHA2DS2VASc 
scores [5, 6].
As documented in this paper, the implementation 
of a simple algorithm of applying OAC to patients with 
a high and an intermediate thromboembolism risk into 
clinical practice is still difficult. In the present study, OAC 
in monotherapy or in therapy combined with antiplatelet 
drugs was recommended for 61% of patients without 
a thromboembolism risk. In the ATRIUM study, up to 66.8% 
of patients without risk factors in CHADS2 score received 
OAC [16]. Waldo et al. [17] indicated the use of OAC among 
participants with a low stroke risk in 40% of hospitalised 
subjects. Chae et al. [25] demonstrated the application 
of OAC in 36% of patients with a low thromboembolism 
risk in a group of 3,086 hospitalised patients with AF. The 
recommendation of OAC for patients without a thrombo-
embolism risk factors results in the unnecessary risk of 
bleeding complications.
In the present study, one of the highest results of 
therapy compliant with the guidelines was reported among 
patients after thromboembolic episodes. Up to 71% of those 
who recovered from a stroke, transient ischaemic attack 
(TIA) or systemic embolism received OAC. In the ATRIA (Anti-
coagulation and Risk Factors in Atrial Fibrillation) study, the 
number of patients after a stroke who received anticoagu-
lant therapy was even higher and amounted to 77% [26]. 
However, in the present study, one-third of patients after 
a thromboembolic episode still received no effective protec-
tion from the recurrence of stroke. The thromboembolism 
risk among these patients was one of many factors taken 
into consideration while recommending the prevention of 
thromboembolic complications. In the majority of patients 
after stroke (primarily over 80 years of age) who did not 
receive OAC, the risk of bleeding was high. In a registry of 
81,381 patients with AF over 60 years of age, the number 
of patients receiving OAC after a thromboembolic episode 
was also reported to decrease with age [22]. The follow-
ing percentage of patients treated with OAC was observed 
among patients after a stroke or TIA in the particular age 
groups: 60–69, 66%; 70–79, 59%; and over 80, 16%. OAC 
was received by a total of 34% of patients with AF after 
a thromboembolic episode [22].
Patients of advanced age, something which increases 
the risk of thromboembolic and simultaneously bleeding 
complications, require particular attention when consi-
dering anticoagulant treatment. In the present study, one 
in five patients was over 80 years old. The application of 
Table 5. Results of using oral anticoagulants in the prevention 
of thromboembolic complications of atrial fibrillation (based on 
[13–24])
Study Study period Oral anticoagu-
lants use [%]
Waldo [17] 2002 55
Agarwal [18] 2003–2004 56
Euro Heart Survey [14] 2003–2004 63
EXAMINE-AF [19] 2004–2005 64
AFNET [15] 2004–2006 59.6
PINNACLE [20] 2008–2009 55.1
ATRIUM [16] 2009 83
Rodríguez-Mañero [21] 2009 62.7
Scowcroft [22] 2000–2009 45.6
Bednarski [23] 2006 and 2010 39
GARFIELD [13] 2009–2011 57
Cowan [24] 2009–2012 54.7
Present study 2004–2012 64
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OAC was recommended for 95% of patients at the age 
of 81 or more, whereas only 55.2% of them received the 
anticoagulant. Results differing from those obtained in the 
present study were achieved in the PINNACLE Registry of 
American patients, which included 9,113 patients with AF 
rated as having either an intermediate or a high risk of 
thromboembolic complications [20]. The age of 81 plus 
was a predictive factor for OAC recommendations, and 
increased the chance of its application by 17%. Spanish 
researchers proved in their study that a positive improve-
ment has been made in recent years in the anticoagulant 
treatment of patients aged over 80 [21]. In Spain, 24% of 
octogenarians received OAC in 1999, whereas in 2009 this 
percentage had increased to 38%. Simultaneously, the 
number of patients in this age group who received anti-
platelet drugs to prevent thromboembolic complications of 
AF has significantly decreased. In this study, advanced age 
was a predictive factor for avoiding OAC recommendations. 
It can be assumed that numerous comorbid conditions and 
disorders of cognitive functions, which are often observed 
in older patients, as well as the lack of proper care for 
geriatric patients, which allows for a safe anticoagulant 
treatment, has contributed to the non-application of anti-
coagulant therapy to patients aged 81 plus.
Study limitations
The present study was retrospective and was conduc-
ted in one research centre. The study involved patients 
hospitalised over a period of nine years. During this 
time, the standards for the treatment of patients with 
AF changed on three occasions. Over the years, the cha-
racteristics of the patients suffering from arrhythmia, the 
conditions which co-existed with AF, and the causes of 
hospitalisation, were also undergoing change. All these 
factors led to the fact that the examined population was 
non-homogenous.
Conclusions
1. Nearly two-thirds of patients with AF were subjected 
to the prevention of thromboembolic complications on 
discharge in accordance with the guidelines. 2. Patients 
with an intermediate thromboembolism risk most often 
received the prevention of thromboembolic complications 
in accordance with the guidelines. 3. The lowest level of 
compliance with the guidelines for anticoagulant treatment 
was reported among patients with a low thromboembolism 
risk, most of whom were treated with oral anticoagulants, 
which led to the risk of bleeding complications. 4. A high 
percentage of patients with atrial fibrillation who were tre-
ated in accordance with the guidelines were patients after 
a thromboembolic episode. 5. The number of patients with 
atrial fibrillation receiving anticoagulant drugs in accordan-
ce with the guidelines decreases with age.
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Streszczenie
Wstęp. Migotanie przedsionków (AF) to najczęstsza arytmia nadkomorowa, a jej następstwami są zwiększona zapa-
dalność na powikłania zakrzepowo-zatorowe i wyższe wskaźniki umieralności. Częstość występowania zaburzeń rytmu 
serca jest coraz większa i oczekuje się również stałego wzrostu liczby chorych z AF. Epizody zakrzepowo-zatorowe są 
najpoważniejszymi powikłaniami AF, a za najistotniejsze postępowanie w tej grupie pacjentów uważa się leczenie prze-
ciwzakrzepowe zgodne z aktualnymi wytycznymi.
Badanie przeprowadzono w celu oceny zgodności z wytycznymi prewencyjnego leczenia przeciwzakrzepowego zalecone-
go w wypisie ze szpitala chorym z niezastawkowym AF, których hospitalizowano na oddziale kardiologii.
Materiał i metody. Do retrospektywnej analizy włączono 4099 chorych z niezastawkowym AF, których wypisano z od-
działu kardiologicznego po hospitalizacji w latach 2004–2012. Oceniono ryzyko powikłań zakrzepowo-zatorowych (skala 
CHADS2) i krwotocznych (skala HAS-BLED), a także dane dotyczące chorób współistniejących oraz zalecanego w ramach 
prewencji leczenia przeciwzakrzepowego. Zgodność z wytycznymi w zakresie zapobiegania powikłaniom zakrzepowo-
-zatorowym oceniono, analizując zastosowane antykoagulanty i leki przeciwpłytkowe w grupach chorych obciążonych 
ryzykiem zakrzepowo-zatorowym o różnym poziomie.
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Wyniki. Średni wiek w badanej grupie wynosił 70,6 (± 10,9) roku. U chorych z AF występowały następujące choroby 
współistniejące: nadciśnienie tętnicze (74,8%), choroba niedokrwienna serca (56,7%), niewydolność serca (54,8%). 
Niskie ryzyko powikłań zakrzepowo-zatorowych stwierdzono u 7,2% chorych, umiarkowane ryzyko — u 25,4%, natomiast 
wysokie ryzyko — u 67,4% chorych. U 34,6% chorych stwierdzono wysokie ryzyko krwawienia. Przyjmowanie w ramach 
prewencji powikłań zakrzepowo-zatorowych doustnych antykoagulantów w monoterapii lub w skojarzeniu z lekami 
przeciwpłytkowymi zalecono w wypisie 64% pacjentów. Zgodnie z wytycznymi do prewencyjnego leczenia przeciwzakrze-
powego kwalifikowało się 66,9% chorych z badanej grupy — 62,4% chorych obciążonych wysokim ryzykiem udaru, 86% 
cechujących się umiarkowanym ryzykiem udaru i 41,1% nieobciążonych czynnikami ryzyka udaru. Najwyższy odsetek 
chorych leczonych zgodnie z wytycznymi odnoszącymi się do danej sytuacji klinicznej obserwowano w grupie chorych 
po epizodzie zakrzepowo-zatorowym (70,8%). Stwierdzono, że prewencyjne leczenie przeciwzakrzepowe zgodne z wy-
tycznymi stosowano u 73,8% chorych w wieku 65–74 lat i 55,2% chorych powyżej 80 lat.
Wnioski. Niemal 2/3 chorych z AF w wypisie ze szpitala zalecono prewencję powikłań zakrzepowo-zatorowych zgodną 
z wytycznymi. Najwięcej spośród tych osób należało do grupy umiarkowanego ryzyka, a najmniej do grypy nieobciążonej 
czynnikami ryzyka zakrzepowo-zatorowego. Znaczny odsetek chorych leczonych zgodnie z wytycznymi zaobserwowano 
w grupie osób, które przebyły epizod zakrzepowo-zatorowy. Odsetek chorych z AF, którym zalecono leki przeciwzakrze-
powe zgodnie z wytycznymi, zmniejszał się z wiekiem.
Słowa kluczowe: migotanie przedsionków, CHADS2, skala, udar
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